相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
Scott C. Jeffrey et al.
BIOCONJUGATE CHEMISTRY (2013)
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Jacob M. Rowe et al.
BLOOD (2013)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
May S. Kung Sutherland et al.
BLOOD (2013)
Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
Pavel Strop et al.
CHEMISTRY & BIOLOGY (2013)
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Sara A. Hurvitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Milatuzumab-SN-38 Conjugates for the Treatment of CD74 Cancers
Serengulam V. Govindan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
Surinder Kaur et al.
BIOANALYSIS (2013)
A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy
Goncalo J. L. Bernardes et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Engineering Folate-Drug Conjugates to Target Cancer: From Chemistry to Clinic
Iontcho R. Vlahov et al.
BIOCONJUGATE CHEMISTRY (2012)
A total synthesis trilogy: Calicheamicin γ1I, Taxol®, and brevetoxin A
K. C. Nicolaou et al.
CHEMICAL RECORD (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer
Robert Yongxin Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Site-Specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery
Giulio Casi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
Robert M. Sharkey et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Hans K. Erickson et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen et al.
NATURE BIOTECHNOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes
Markus Heine et al.
PLOS ONE (2012)
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Jun Y. Axup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Design of Antibody-Maytansinoid Conjugates Allows for Efficient Detoxification via Liver Metabolism
Xiuxia Sun et al.
BIOCONJUGATE CHEMISTRY (2011)
Disulfide-Linked Antibody-Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage
Brenda A. Kellogg et al.
BIOCONJUGATE CHEMISTRY (2011)
Site-specific modification of ED-B-targeting antibody using intein-fusion technology
Sina Moehlmann et al.
BMC BIOTECHNOLOGY (2011)
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
John F. DiJoseph et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Highly potent antibody-amanitin conjugates cause tumor-selective apoptosis
Jan Anderl et al.
CANCER RESEARCH (2011)
Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
Stephen I. Rudnick et al.
CANCER RESEARCH (2011)
Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)
Dyeison Antonow et al.
CHEMICAL REVIEWS (2011)
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Thomas M. Cardillo et al.
CLINICAL CANCER RESEARCH (2011)
An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours
Rebecca K. Kelly et al.
EUROPEAN JOURNAL OF CANCER (2011)
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates
Robert Y. Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Analytical methods for physicochemical characterization of antibody drug conjugates
Aditya Wakankar et al.
MABS (2011)
SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity
John A. Hartley et al.
CANCER RESEARCH (2010)
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena V. Kovtun et al.
CANCER RESEARCH (2010)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
Manu Lopus et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates
Serengulam V. Govindan et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors
Daniel Hochhauser et al.
CLINICAL CANCER RESEARCH (2009)
How do anti-mitotic drugs kill cancer cells?
Karen E. Gascoigne et al.
JOURNAL OF CELL SCIENCE (2009)
The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
Stephen C. Alley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Designing potent antibody-drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity
Erin Maloney et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Potent antigen-specific anti-tumor activity observed with antibody-drug conjugates (ADCs) made using a new class of DNA-crosslinking agents
Michael Miller et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Discovery and development of folic-acid-based receptor targeting for Imaging and therapy of cancer and inflammatory diseases
Philip S. Low et al.
ACCOUNTS OF CHEMICAL RESEARCH (2008)
Monoclonal antibodies in cancer therapy: 25 years of progress
Robert K. Oldham et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
Sung-Ju Moon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Kristine M. Kim et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
CD74: A new candidate target for the immunotherapy of B-Cell neoplasms
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2007)
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Preclinical evaluation of EC145, a folate-Vinca alkaloid conjugate
Joseph A. Reddy et al.
CANCER RESEARCH (2007)
Semisynthetic maytansine analogues for the targeted treatment of cancer
Wayne C. Widdison et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97
Leia M. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
HK Erickson et al.
CANCER RESEARCH (2006)
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MSK Sutherland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization
JD Orth et al.
CANCER RESEARCH (2006)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
CL Law et al.
CANCER RESEARCH (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2005)
A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2005)
A passionate kiss, then run: exocytosis and recycling of IgG by FcRn
WI Lencer et al.
TRENDS IN CELL BIOLOGY (2005)
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
AC Lazar et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2005)
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity.: Part 1:: Cellular pharmacology, in vitro and initial in vivo antitumor activity
JA Hartley et al.
CANCER RESEARCH (2004)
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
MC Alley et al.
CANCER RESEARCH (2004)
Recent developments in the maytansinoid antitumor agents
JM Cassady et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
A convergent approach to cryptophycin 52 analogues: Synthesis and biological evaluation of a novel series of fragment A epoxides and chlorohydrins
RS Al-Awar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
MJ Edelman et al.
LUNG CANCER (2003)
Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
M. Abal et al.
CURRENT CANCER DRUG TARGETS (2003)
Phase II trial of KW2189 in patients with advanced malignant melanoma
SN Markovic et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity
SJ Gregson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Site-specific conjugation on serine → cysteine variant monoclonal antibodies
JB Stimmel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
N Pavlidis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
分享论文
